Regenerative Medicine (RM) and Cell therapy (CT) provide concrete answers to unmet health needs with tremendous benefits to the patients. This market represents a considerable business opportunity for research and clinical applications concerning cells transplanted into human patients. Cell therapies and TERM are based on cells isolated from donor (or autologous) tissue and transplanted into patients. Cell isolation from organ or tissues represents a critical step: not only a high number of living and functional cells needs to be isolated, but also reproducible protocols and results are necessary. Ongoing protocols determine unpredictable enzymatic efficiency, low batch consistency, and low stability, which can cause drawbacks in the efficiency of cell extraction and low reproducibility as well as standardization of protocols itself. Here is the best-patented company goal.